Rita Jervis

Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD; BBSE: DRP) announces that the Company and Oriental Wave Holding Limited have agreed to extend the Share Purchase Agreement to February 28, 2005 in connection with the proposed acquisition of Oriental Wave. Under the original terms of the Share Purchase Agreement, the acquisition was to be completed […]

Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG; BBSE: DRP) is pleased to announce the results for the third quarter ended September 30, 2004. For the three-month ended September 30, 2004 During the third quarter in 2004, the Company posted revenues of $1,057,254 from the sales of rHu Erythropoietin (EPO) compared to $1,151,646 for the […]

Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG; BBSE: DRP) today announced that 2.23 million common shares of the Company have been placed in escrow by Dr. Liu, a director of the Company, to secure the debt obligation to the Company pursuant to the Settlement Agreement among Dragon, Dr. Liu and Novagen Holding Inc., Dr. […]

Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) is pleased to announce the results for the first quarter ending March 31, 2004. During the quarter, the Company posted revenues of $878,270 from the sales of rHu Erythropoietin (EPO), which represents 32.2% growth from the same period in 2003. Revenues of $701,870 were generated from sales […]

Dragon Pharmaceutical Inc. (TSX: DDD, OTC BB: DRUG) (“Dragon”) is pleased to announce that it has entered into a letter of intent to combine with Oriental Wave Holding Ltd (“Oriental Wave”) and its subsidiary (together as “Oriental Wave Group”) in a merger by which Dragon shareholders would own 31.65% of the new entity and Oriental […]

Dragon Pharmaceutical Inc. (TSX: DDD, OTC BB: DRUG) (“Dragon”) today updates its previously announced Letter of Intent to merge with Oriental Wave Holding Limited (“Oriental Wave”). Oriental Wave’s auditor, an accounting firm registered with the Public Company Accounting Oversight Board, has completed its audit and issued its report on Oriental Wave’s 2003 financial statements. Oriental […]

Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) announced the completion of the Company’s Annual General Meeting held in Vancouver on June 26, 2003. The shareholders have re-elected the following five members of the Board of Directors. Dr. Alexander Wick, President and Chief Executive Officer Dr. Longbin Liu, M.D., Chairman of the Board of Directors […]

During the third quarter of 2003, Dragon signed a development agreement with a European research institute to collaborate in developing a new cell line and proprietary production process for a newly developed EPO product for the European market. In addition, Dragon has completed an upgrade of its current production facility in Nanjing, China, doubling the […]

Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced results for the three-month and twelve-month periods ending December 31, 2003. Highlights Generated revenues of $3.65 million and a net loss of US$1.99 million, or $0.10 per share for the full year of 2003. Continued momentum in developing the International market: Launched rh-Erythropoietin (“EPO”) into […]